Soluble Receptor Level of Advanced Glycation (sRAGE) Products in Serum in Patients with Systemic Lupus Erythematosus:

Serdar Gök; Burak Okyar; Defne Ay Tuncel; Fatma İnanç Tolun; Filiz Alkan Baylan; Can Acıpayam; Adem Doğaner; Gözde Yıldırım Çetin

Makale detayları

Soluble Receptor Level of Advanced Glycation (sRAGE) Products in Serum in Patients with Systemic Lupus Erythematosus:

Yazarlar:

Serdar Gök | Burak Okyar | Defne Ay Tuncel | Fatma İnanç Tolun | Filiz Alkan Baylan | Can Acıpayam | Adem Doğaner | Gözde Yıldırım Çetin

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 2, pp.29-34

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001322849

pISSN:

1303-6610

Anahtar kelimeler:

Özet:

 Objectives: Systemic Lupus Erythematosus SLE is an autoimmune disease characterized by antibody formation against nuclear autoantigens. A receptor for Advanced Glycation RAGE is produced by many immune system cells, such as neutrophils, macrophages, and T cells, and interacts with many classes of ligands. In light of these results, the level of sRAGE, the soluble form of RAGE, may be associated with disease activity. In light of this information, we aimed to evaluate whether there is a relationship between plasma sRAGE levels and SLE. Materials and Methods: Eighteen patients diagnosed with SLE MF: 117 and twenty-one patients without any disease diagnosis MF: 219 were included as the control group. In these patients, plasma sRAGE level was measured by ELIZA method using an ELIZA enzyme-linked immunosorbent assay kit BioVendor Research and Diagnostic Products. The data obtained were compared between the groups. Results: The mean plasma sRAGE level was lower in patients with SLE than in healthy control patients but not statistically significant p0.966. Our study found a positive correlation between SLEDAI and sRAGE levels in patients with SLE r0.628, p0.005. Although no significant correlation was found between patients with SLE, sRAGE levels were positively correlated between fourteen patients classified as active SLE and the control group. Conclusions: In our study, we found that plasma sRAGE levels in patients with SLE were lower than in healthy controls, but plasma sRAGE levels in patients with active SLE were higher than plasma sRAGE levels in patients with inactive SLE. We hypothesized that reduced sRAGE levels in patients with SLE could be explained by the depletion of this soluble receptor. Our study differed from another similar study showing that blood sRAGE levels were higher in patients with SLE than in healthy controls. Blood sRAGE levels were significantly increased during active disease compared with patients with quiescent SLE.

 Objectives: Systemic Lupus Erythematosus SLE is an autoimmune disease characterized by antibody formation against nuclear autoantigens. A receptor for Advanced Glycation RAGE is produced by many immune system cells, such as neutrophils, macrophages, and T cells, and interacts with many classes of ligands. In light of these results, the level of sRAGE, the soluble form of RAGE, may be associated with disease activity. In light of this information, we aimed to evaluate whether there is a relationship between plasma sRAGE levels and SLE. Materials and Methods: Eighteen patients diagnosed with SLE MF: 117 and twenty-one patients without any disease diagnosis MF: 219 were included as the control group. In these patients, plasma sRAGE level was measured by ELIZA method using an ELIZA enzyme-linked immunosorbent assay kit BioVendor Research and Diagnostic Products. The data obtained were compared between the groups. Results: The mean plasma sRAGE level was lower in patients with SLE than in healthy control patients but not statistically significant p0.966. Our study found a positive correlation between SLEDAI and sRAGE levels in patients with SLE r0.628, p0.005. Although no significant correlation was found between patients with SLE, sRAGE levels were positively correlated between fourteen patients classified as active SLE and the control group. Conclusions: In our study, we found that plasma sRAGE levels in patients with SLE were lower than in healthy controls, but plasma sRAGE levels in patients with active SLE were higher than plasma sRAGE levels in patients with inactive SLE. We hypothesized that reduced sRAGE levels in patients with SLE could be explained by the depletion of this soluble receptor. Our study differed from another similar study showing that blood sRAGE levels were higher in patients with SLE than in healthy controls. Blood sRAGE levels were significantly increased during active disease compared with patients with quiescent SLE.

 Objectives: Systemic Lupus Erythematosus SLE is an autoimmune disease characterized by antibody formation against nuclear autoantigens. A receptor for Advanced Glycation RAGE is produced by many immune system cells, such as neutrophils, macrophages, and T cells, and interacts with many classes of ligands. In light of these results, the level of sRAGE, the soluble form of RAGE, may be associated with disease activity. In light of this information, we aimed to evaluate whether there is a relationship between plasma sRAGE levels and SLE. Materials and Methods: Eighteen patients diagnosed with SLE MF: 117 and twenty-one patients without any disease diagnosis MF: 219 were included as the control group. In these patients, plasma sRAGE level was measured by ELIZA method using an ELIZA enzyme-linked immunosorbent assay kit BioVendor Research and Diagnostic Products. The data obtained were compared between the groups. Results: The mean plasma sRAGE level was lower in patients with SLE than in healthy control patients but not statistically significant p0.966. Our study found a positive correlation between SLEDAI and sRAGE levels in patients with SLE r0.628, p0.005. Although no significant correlation was found between patients with SLE, sRAGE levels were positively correlated between fourteen patients classified as active SLE and the control group. Conclusions: In our study, we found that plasma sRAGE levels in patients with SLE were lower than in healthy controls, but plasma sRAGE levels in patients with active SLE were higher than plasma sRAGE levels in patients with inactive SLE. We hypothesized that reduced sRAGE levels in patients with SLE could be explained by the depletion of this soluble receptor. Our study differed from another similar study showing that blood sRAGE levels were higher in patients with SLE than in healthy controls. Blood sRAGE levels were significantly increased during active disease compared with patients with quiescent SLE.

 Amaç: Sistemik Lupus Eritematozus SLE nükleer otoantijenlere karşı antikor oluşumu ile karakterize otoimmün bir hastalıktır. İleri Glikasyon Reseptörü RAGE nötrofiller, makrofajlar ve T hücreleri gibi birçok bağışıklık sistemi hücresi tarafından üretilir ve birçok ligand sınıfı ile etkileşime girer. Bu sonuçlar ışığında, RAGEnin çözünebilir formu olan sRAGE seviyesi hastalık aktivitesi ile ilişkili olabilir. Bu bilgiler ışığında, plazma sRAGE düzeyleri ile SLE arasında bir ilişki olup olmadığını değerlendirmeyi amaçladık. Gereç ve Yöntem: SLE tanısı konmuş on sekiz hasta EK: 117 ve herhangi bir hastalık tanısı olmayan yirmi bir hasta EK: 219 kontrol grubu olarak çalışmaya dahil edildi. Bu hastalarda plazma sRAGE düzeyi ELIZA enzyme-linked immunosorbent assay kiti BioVendor Research and Diagnostic Products kullanılarak ELIZA yöntemi ile ölçüldü. Elde edilen veriler gruplar arasında karşılaştırıldı. Bulgular: Ortalama plazma sRAGE düzeyi SLE hastalarında sağlıklı kontrol hastalarına göre daha düşüktü ancak istatistiksel olarak anlamlı değildi p0.966. Çalışmamızda SLEli hastalarda SLEDAI ve sRAGE düzeyleri arasında pozitif bir korelasyon bulundu r0.628, p0.005. SLEli hastalar arasında anlamlı bir korelasyon bulunmamasına rağmen, aktif SLE olarak sınıflandırılan on dört hasta ile kontrol grubu arasında sRAGE düzeyleri pozitif korelasyon göstermiştir. Sonuç: Çalışmamızda, SLEli hastalarda plazma sRAGE düzeylerinin sağlıklı kontrollere göre daha düşük olduğunu, ancak aktif SLEli hastalarda plazma sRAGE düzeylerinin inaktif SLEli hastalardaki plazma sRAGE düzeylerinden daha yüksek olduğunu bulduk. SLEli hastalarda sRAGE düzeylerindeki azalmanın bu çözünür reseptörün tükenmesi ile açıklanabileceğini varsaydık. Çalışmamız, SLEli hastalarda kan sRAGE düzeylerinin sağlıklı kontrollere göre daha yüksek olduğunu gösteren benzer bir başka çalışmadan farklıydı. Kan sRAGE düzeyleri, aktif hastalık sırasında, sakin SLE hastalarına kıyasla önemli ölçüde artmıştır.

Makale detayları

Soluble Receptor Level of Advanced Glycation (sRAGE) Products in Serum in Patients with Systemic Lupus Erythematosus:

Yazarlar:

Serdar Gök | Burak Okyar | Defne Ay Tuncel | Fatma İnanç Tolun | Filiz Alkan Baylan | Can Acıpayam | Adem Doğaner | Gözde Yıldırım Çetin

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 2, pp.29-34

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001322849

pISSN:

1303-6610

Systemic Lupus Erythematosus

sRAGE

Disease ActivitySistemik Lupus Eritematozus

sRAGE

Hastalık Aktivitesi

Sayı

Makale detayları

Soluble Receptor Level of Advanced Glycation (sRAGE) Products in Serum in Patients with Systemic Lupus Erythematosus:

Yazarlar: Serdar Gök | Burak Okyar | Defne Ay Tuncel | Fatma İnanç Tolun | Filiz Alkan Baylan | Can Acıpayam | Adem Doğaner | Gözde Yıldırım Çetin

Yayıncı: Kahramanmaras Sutcu Imam University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 2, pp.29-34

Belge Tipi: Makale

Yayın Tarihi: 7/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001322849

pISSN: 1303-6610

Systemic Lupus Erythematosus

sRAGE

Disease ActivitySistemik Lupus Eritematozus

sRAGE

Hastalık Aktivitesi

Sayı

Yazarlar:

Serdar Gök | Burak Okyar | Defne Ay Tuncel | Fatma İnanç Tolun | Filiz Alkan Baylan | Can Acıpayam | Adem Doğaner | Gözde Yıldırım Çetin

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 2, pp.29-34

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001322849

pISSN:

1303-6610